Centus Gets European Bevacizumab Approval
Equidacent Rival To Avastin Gains Marketing Authorization
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
You may also be interested in...
Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.
Centus Biotherapeutics and Roche’s Genentech have agreed to settle US patent litigation over the biosimilars firm’s FKB238 proposed bevacizumab rival to Avastin.
Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.